EGFR and HER2 genomic gain in recurrent non-small cell lung cancer after surgery: impact on outcome to treatment with gefitinib and association with EGFR and KRAS mutations in a Japanese cohort.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples